Celecoxib Exhibits the Greatest Potency amongst Cyclooxygenase (COX) Inhibitors for Growth Inhibition of COX-2-negative Hematopoietic and Epithelial Cell Lines

摘要: Cyclooxygenase-2 (COX-2) is an important cellular target for both therapy and/or prevention of inflammatory disorders and cancer. The advent selective COX-2 inhibitors now allows a more precise safer treatment approach. screening array cancer cell lines growth inhibitory effects COX-2-selective -nonselective inhibitors, including celecoxib (Celebrex) rofecoxib (Vioxx), produced two unanticipated findings. Firstly, the antiproliferative were noted to be very similar magnitude hematopoietic epithelial lines. Most had no detectable expression by reverse transcription-PCR, none expressed protein. In addition, COX-2-negative found have IC50s that their COX-2+ counterparts. Thus, observed independent lineage status. Secondly, it was also inhibitor drugs, rofecoxib, with COX-2-selectivity clinical efficacy indications, differed significantly in vitro on 35–65 μm across this entire panel Finally, difference mode or degree cytotoxicity apparent between lines, because levels apoptosis -negative after celecoxib, correspondingly lower treatment. These data are they provide first direct comparison as well anticancer clinically available inhibitors.